We previously demonstrated that the switch from non-to highly tumorigenic phenotype of human melanoma cells is directly related to procathepsin L secretion, which increased cell resistance to complement-mediated cell lysis. Involvement of procathepsin L secretion in tumor growth was clearly demonstrated by three different strategies: (1) inhibition of secreted procathepsin L activity; (2) increase of procathepsin L secretion; and (3) inhibition of procathepsin L secretion. This latter strategy was triggered by intracellular expression of anti-human cathepsin L single-chain variable fragment (ScFv). These previous experiments were performed by processing melanoma cells before their injection into nude mice. We herein designed a new lentiviral vector in which this anti-cathepsin L ScFv was cloned. This lentiviral vector was optimized to allow the highest intracellular expression of anticathepsin L ScFv in transduced melanoma cells. In these transduced cells, procathepsin L secretion was strongly inhibited. In addition, injection of this anti-cathepsin L ScFv lentiviral vector into tumors already induced in nude mice inhibited tumor growth and associated angiogenesis. This is the first report to demonstrate that targeting procathepsin L secretion with anti-cathepsin L ScFv lentiviral construct constitutes a new gene therapy in the challenge to inhibit the growth of tumors induced by human melanoma cells.
Introduction
The switch of human melanoma phenotype from non-to highly tumorigenic and metastatic is under the control of intracellular and extracellular molecular events and the organ microenvironment. 1 Among these, the resistance of human melanoma cells to the immune system is an important aspect. In this field, the molecules involved in the resistance of melanoma cells to complement-mediated cell lysis needed to be known. This led us to identify proteinases characterized, on the one hand, by their localization at the cell surface and, on the other, by their property to cleave human C3, the third component of complement. 2, 3 Indeed, cleavage of human C3, the pivotal component of complement, inhibits its deposition on cell surface and the activation of complement pathways, consequently inhibiting complement-mediated cell lysis. In addition, C3 cleavage generates C3 fragments involved in a broad spectrum of cell regulations and biological functions, through at least six distinct and specific cell surface C3 receptors. [4] [5] [6] We previously demonstrated that highly tumorigenic and metastatic human melanoma cells express and secrete a 41 kDa cysteine proteinase, identified as procathepsin L, which cleaves human C3 at pH 7.5. Procathepsin L contributes at least 60% to melanoma cell resistance to complement-mediated cell lysis. [7] [8] [9] [10] Procathepsin L is the proenzyme of cathepsin L, a papain-type cysteine proteinase, [11] [12] [13] whose gene is located on human chromosome 9q21-22.
14 In normal cells, cathepsin L, first translated as pre-procathepsin L, is transferred through the Golgi apparatus as procathepsin L and then stored in lysosomes as mature cathepsin L. In addition, in tumor cells, procathepsin L is also secreted, as compared with normal cells. [15] [16] [17] Thus, cathepsin L acts as an endopeptidase, which degrades a wide range of intracellular cytoplasmic and nuclear proteins, 13 and, when secreted as procathepsin L, also extracellular proteins. [7] [8] [9] [10] Our previous data emphasized that the increase of procathepsin L secretion is a major event involved in the switch of human melanoma phenotype to highly tumorigenic and strongly metastatic. Indeed, this was supported by three complementary demonstrations. First, pretreatment of highly tumorigenic and metastatic human melanoma cells by polyclonal anti-cathepsin L (anti-CTSL) antibodies, which inhibit cathepsin L proteinase activity, prevented tumor formation and decreased by 50% metastasis development in lungs of nude mice. 8 Second, stable transfection by cathepsin L cDNA of human melanoma cells, characterized by low tumorigenic and non-metastatic phenotype, led to the generation of clones that secreted a higher level of procathepsin L. 10 These transfected clones carried higher C3-cleaving activity and consequently higher resistance to complement-mediated lysis than the parental cells. Furthermore, their phenotype switched to highly tumorigenic and strongly metastatic in nude mice. 10 Third, to specifically inhibit procathepsin L secretion in human melanoma cells, we designed an anti-human CTSL single-chain variable fragment (ScFv) from an anti-CTSL monoclonal antibody (moAb) generated using recombinant cathepsin L as immunogen. 18 Sequences and binding properties of this anti-CTSL-ScFv were determined. 18 Then, we demonstrated that in vitro stable transfection with the cytomegalovirus promoter (pCMV)/myc/ER-anti-CTSLScFv expression vector of A375SM human melanoma cells, characterized by a high tumorigenic and strong metastatic phenotype, led to: (1) intracellular expression of anti-human CTSL-ScFv; (2) strong inhibition of procathepsin L secretion by transfected cells, without modifying their intracellular amount or processing pattern of cathepsin L forms; and (3) switch their phenotype to very poorly tumorigenic and non-metastatic. 19 In vivo, cells transfected with this anti-CTSLScFv produced less and smaller tumors with a decrease of vascularization (angiogenesis) and an increase of cell apoptosis. 19 Furthermore, our recent demonstrations that overexpression of cathepsin L in human tumor cells is under the control of separate and complex regulatory mechanisms 20, 21 support that procathepsin L secretion is a key event on which we should focus to inhibit tumorigenic and metastatic phenotype of human melanoma. As detailed above, our previous experiments were performed by processing human melanoma cells before their injections in nude mice, with polyclonal anti-CTSL antibodies, 8 cathepsin L cDNA 10 or anti-CTSL-ScFv. 18, 19 Thus, we herein analyzed whether it is possible to inhibit later the growth of human tumors already induced in nude mice. For this purpose, we cloned the anti-CTSLScFv in a lentiviral vector construct, optimized to allow in vitro high-transduction efficiency of human melanoma cells. Transduced melanoma cells expressed the anti-CTSL-ScFv, and their procathepsin L secretion was strongly inhibited. In addition, the intratumoral injection of anti-CTSL-ScFv lentiviral vector into subcutaneous (s.c.) tumors already induced in nude mice inhibited tumor growth and associated angiogenesis.
Materials and methods

Cell lines and culture conditions
The highly tumorigenic and metastatic human melanoma A375SM cell line was established from nude mice lung metastases produced by the A375 human cell line isolated from a lymph node metastasis and grown as described previously. 19 The human embryonic kidney 293FT cells (Invitrogen, Cergy Pontoise, France) were grown as adherent monolayers in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10% (v/v) fetal calf serum, Glutamax-1 (2 mM), non-essential amino acids (0.1 mM), Glucose (4.5 g l
À1
), sodium pyruvate (1 mM), Geneticin (500 mg ml
) and penicillin (100 U ml
)/ streptomycin (100 mg ml À1 ) (Invitrogen) at 37 1C in a CO 2 incubator.
Hypoxia treatment
Cells were grown under hypoxic conditions at 37 1C within a modular incubator chamber (Billups-Rothenberg, 
Plasmid constructs
The sequence of the primers used in the amplification of individual domains is detailed in Table 1 . PCR products were generated using GeneAmp High-Fidelity DNA polymerase (Applied Biosystems, Courtaboeuf, France) and were digested with the appropriate endonucleases prior to ligation and subcloning. Each construct was controlled by sequence analysis (Genome Express, Grenoble, France).
Generation of ScFv expression vector with different signal peptides. The anti-CTSL-ScFv was cloned in pCMV/ myc/ER vector (Invitrogen) as a fusion protein with a N-terminal signal peptide (sp), an endoplasmic reticulum retention signal (peptide SEKDEL) and a c-myc epitope at the C terminus. 18, 19 Cathepsin L sp with or without its 5 0 -untranslated region (5 0 -UTR) was amplified from A375SM melanoma cells cDNA. The longest (5 0 -UTR-A) and the shortest (5 0 -UTR-A3) 5 0 -UTR used a splicing donor site located at 1211 and 1355 bp from the translation initiation site, respectively. A mouse V H chain sp without intron was generated by two rounds of PCR. Briefly, the two exons of mouse V H chain sp were first amplified separately from pCMV/myc/ER vector using overlapping primers and then were assembled by fusion PCR with the outermost primers. The mouse V H chain sp, which contains an intron in pCMV/myc/ER-anti-CTSLScFv vector, 19 was substituted by these PCR products using PmlI and SalI restriction sites to generate expression vectors encoding ScFv coupled to different sps.
Construction of lentiviral transfer vector. Lentiviral transfer vectors encoding anti-CTSL-ScFv were generated using the pLenti6/V5-D-TOPO vector (Invitrogen, ViraPower Lentiviral Expression System). The NdeI-XbaI DNA fragments (containing part of the CMV promoter, the sp, the anti-CTSL-ScFv cDNA, the endoplasmic reticulum retention signal SEKDEL and the c-myc epitope), from the pCMV/myc/ER vectors encoding ScFv coupled to different sps, were subcloned into the pLenti6/ V5-D-TOPO vector. The subsequent modifications were performed in the plenti6-spCTSL-ScFv-Blast vector, which contains the anti-CTSL-ScFv cDNA coupled to cathepsin L peptide signal. The V5 epitope, the SV40 early promoter and the blasticidin resistance gene were replaced by the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) by using ApaI and KpnI restriction sites, or they were deleted by fill in reaction and blunt-end ligation to generate the plenti6-spCTSL-anti-CTSL-ScFv-WPRE and plenti6-spCTSLanti-CTSL-ScFv vectors, respectively. Plenti6-spCTSLanti-CTSL-ScFv-IRES-AcGFP or plenti6-spCTSL-anti-CTSL-ScFv-IRES-AcGFP-WPRE vectors were constructed by subcloning the internal ribosome entry site (IRES) of the encephalomyocarditis virus and the Aequorea coerulescens green fluorescent protein (AcGFP) coding region from the pIRES2-AcGFP1 vector (Clontech, Mountain View, CA, USA) into the XbaI restriction site of the plenti6-spCTSL-anti-CTSL-ScFv and plenti6-spCTSL-ScFv-WPRE vectors. An HIV-1 central polypurine tract (cPPT) element was introduced in the plenti6-spCTSL-anti-CTSL-ScFv-IRES-AcGFP-WPRE vector in the ClaI restriction site to generate the plenti6-cPPTspCTSL-anti-CTSL-ScFv-IRES-AcGFP-WPRE vector. In the lentiviral transfer vectors used as control, anti-CTSL-ScFv cDNA vector was deleted by SalI and NotI digestion, fill in reaction and blunt-end ligation.
Production of lentiviral vectors
Vesicular stomatitis virus G protein (VSV-G)-pseudotyped lentiviral vector particles were prepared, using a four-plasmid system, by the transfection of 293FT cells as described in the ViraPower Lentiviral Expression System (Invitrogen). Briefly, 293FT cells were transfected using Lipofectamine 2000 (Invitrogen) with the transfer vector and the three packaging plasmids (pLP1, pLP2 and pLP/ VSV-G). Sixteen hours after transfection, the cells were washed with phosphate-buffered saline (PBS), and a fresh culture medium without Geneticin and antibiotic was added. Twenty-four hours later, the culture supernatant was collected, filtered though 0.45 mm pore size filters and used as the virus stock. The viral p24 antigen concentration was assessed using the HIV-1 p24 Antigen EIA (Beckman Coulter, Villepinte, France). For in vivo experiments, the lentiviral vectors carrying the VSV-G envelope were concentrated by ultracentrifugation in a Beckman centrifuge using a SW41 rotor at 50 000 g at 4 1C for 90 min and suspended in PBS. To determine viral titer, serial dilutions of the concentrated lentiviral preparation were layered over A375SM cells that had been seeded into 24-well culture plates at 2 Â 10 4 cells per well the day before transduction. After 16 h at 37 1C, the supernatant was replaced by a fresh medium. AcGFP expression was detected 72 h later by epifluorescence microscopy, and the titer was calculated and expressed as transducing units per milliliter (TU/ml) of supernatant. Multiplicity of infection (MOI) was calculated based on colony-forming units. Fluorescence intensity was quantified on total cell extracts using a Victor 2 multi-well fluorimeter (Wallac, PerkinElmer, Courtaboeuf, France) and normalized to protein concentration.
Lentiviral in vitro transduction of melanoma cells
For lentiviral transduction, A375SM cells were plated overnight in 24-well plates at a density of 2 Â 10 4 cells per well to allow their attachment. Then, the medium was replaced with 250 ml fresh complete medium containing lentiviral supernatant normalized to the same p24 antigen concentration or the same viral titer and 6 mg ml À1 hexadimethrine bromide (Sigma, Saint-Quentin Fallavier, France) to facilitate the uptake of viral particles. After 16 h at 37 1C, the supernatant was replaced with fresh medium and the cells were expanded. Transduced cells were analyzed for ScFv production, intracellular cathepsin L expression and procathepsin L secretion, as already Tumor inhibition by anti-cathepsin L ScFv delivery R Frade et al described, 19 using the following antibodies: anti-CTSL moAb (clone 3D8) prepared in our laboratory, 18 anti-myc tag moAb (clone 9E10; Upstate Biotechnology, Millipore, Molsheim, France) to detect myc-tagged anti-CTSLScFv, anti-V5-Tag moAb (MCA1360; Serotec, Du¨sseldorf, Germany) to detect V5-tagged procathepsin L, antiglyceraldehyde-3-phosphate dehydrogenase (GAPDH) moAb (mAb374; Chemicon International, Millipore, Molsheim, France) and anti-matrix metalloproteinase 2 (MMP-2) moAb (Ab-3; Calbiochem, Nottingham, UK).
Transient cell transfections A375SM melanoma cell transfection and preparation of cell extracts and extracellular media (which corresponded to culture media without fetal calf serum conditioned by cells) were carried out as previously described. 18, 19 Transfections were performed with 1 mg of the mammalian expression vector pcDNA3.1/V5-His-ProCTSL, which allows expression of a fusion protein of procathepsin L with a C-terminal V5 epitope and 1 mg of pCMV/ myc/ER vectors encoding ScFv coupled to different sps.
Immunofluorescence microscopy analysis Cells exponentially growing on glass slides were fixed with 4% paraformaldehyde for 10 min and then permeabilized with PBS containing 0.1% (v/v) Triton X-100 for 10 min at room temperature. After saturation in PBS containing 4% bovine serum albumin for 45 min, cells were incubated with rabbit Living Colors A.v. polyclonal anti-peptide antibody (anti-GFP) at 2 mg ml À1 (Clontech), to enhance AcGFP signal, as its fluorescence was reduced after paraformaldehyde fixation, and with mouse antimyc tag moAb at 5 mg ml À1 (clone 9E10; Upstate Biotechnology), to detect anti-CTSL-ScFv, for 1 h at room temperature. The cells were washed and then incubated with Alexa Fluor 488 goat anti-rabbit IgG (H þ L) and Alexa Fluor 546 goat anti-mouse IgG (H þ L) at 2 mg ml À1 (Molecular Probes) for 1 h at room temperature. The washed cells were embedded in the Prolong Antifade mounting medium (Molecular Probes). Computer-assisted image analysis of fluorescence was performed using an Olympus BH-2 fluorescence microscope and an AxioCam digital camera (Carl Zeiss, Jena, Germany).
In vitro growth assay A375SM melanoma cells transduced or non-transduced with lentiviral vectors were plated in complete media in 96-well plates at 1 Â 10 3 cells per well. Proliferation was measured using the Celltiter Aqueous One 96 Kit (Promega) as recommended by the manufacturer. The conversion of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium to formazan by metabolically viable cells was monitored by measuring absorbance at 490 nm.
Animals
Male athymic BALB/c nude mice of 6-7 weeks of age were used. They were purchased from Charles River Laboratories (L'Arbresle, France). The mice were housed in laminar flow cabinets under specific pathogen-free conditions in the Center for Exploration and Experimental Functional Research (CERFE) of Evry. Animal facilities and experimental protocols were approved by the French authorities, that is by the Ministe`re de l'Education Nationale de l'Enseignement Supe´rieur et de la Recherche, Comite´National de Ge´nie Ge´ne´tique, Ministe`re de l'Agriculture and by INSERM.
In vivo tumor growth A375SM cells were transduced in vitro with either anti-CTSL-ScFv or control lentiviral vectors 2 weeks before injection and expanded to obtain the required amount. Transduced or non-transduced A375SM cells were harvested and suspended in Hank's buffer. Then, 10 6 cells in a 200 ml volume were injected s.c. into nude mice, over the right scapular region, at day 0, using five mice per group. Growth of tumors was monitored by measuring the tumor size of each mouse with calipers at the indicated days. Tumor volume was calculated using the formula {(length Â width Â height) Â pi/6 (i.e. 0.52)}. The data represent the mean value ± s.d. calculated for each group. After 7 and 10 days of tumor growth, 100 ml of concentrated lentiviral vector preparation (2.3 Â 10 6 or 4 Â 10 6 TU per mouse) were injected into the tumors. Monitoring of tumor growth was performed at days 7, 11 and 15 and then every 5 days up to day 35. The mice were killed 35 days after cell injection, and tumors were processed for hematoxylin and eosin staining.
Immunohistochemistry, immunofluorescence staining and TUNEL labeling of tissue sections Tissue sections were analyzed by terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) and immunochemistry using CD31 antibody as previously described. 19 Analysis of anti-CTSL-ScFv expression by immunofluorescence was performed on tissue section fixed in alcohol-formaldehyde-acetic acid mixture using the same protocol described previously for cells growing on glass slides. Slides were analyzed using Optima 6.5 imaging software. Average microvessel density (MVD) was determined by counting positive staining cells with an adjacent lumen in five random fields per slide (three slides per group).
19 TUNEL results were presented as the percentage of apoptotic cells by examining eight fields per slide and three slides per group.
Statistical analysis
P-values were calculated on tumor volume by using the twotailed Student's t-test and were considered significant and different from controls when P-value was less than 0.03. Other data were analyzed using the Mann-Whitney test.
Results
From the data detailed above, we cloned the anti-CTSLScFv 18, 19 in a lentiviral vector, and as a first step, we analyzed its efficiency in vitro to transduce the anti-CTSLScFv in A375SM melanoma cells.
Selection of the lentiviral vector encoding anti-CTSL-ScFv
The anti-CTSL-ScFv was previously expressed in human melanoma cells as a fusion protein with a N-terminal sp; it was from a mouse V H chain and contains an intron (sp Ig( þ intron)). Other sps were linked to anti-CTSL-ScFv cloned in the pCMV/myc/ER expression vector, and their impacts on ScFv expression were analyzed after transient transfection in A375SM melanoma cells. The sps were either from the same mouse V H chain without intron (spIg (-intron)) or from cathepsin L without (spCTSL) or with 5 0 -UTR. ScFv with cathepsin L sp was also linked either to the longest 5 0 -UTR (spCTSL (5 0 -UTR-A)) or to the shortest 5 0 -UTR (spCTSL (5 0 -UTR-A3)). Protein levels were compared in each intracellular or extracellular sample carrying similar GAPDH or MMP-2 levels, respectively, and used as loading controls. The expression of the 30 kDa anti-CTSL-ScFv was analyzed by western blot using anti-myc tag moAb, in total extracts prepared from cells transfected with these different constructs ( Figure 1a, lanes 2-7) . To analyze the effect of these anti-CTSL-ScFv constructs on procathepsin L secretion, A375SM melanoma cells were co-transfected with an expression vector encoding procathepsin L with a C-terminal V5 epitope (pcDNA3.1/V5-His-ProCTSL) and the vectors encoding anti-CTSL-ScFv linked to these sps. Expression of the 44 kDa ectopic procathepsin L was analyzed by western blot, using anti-V5 moAb, in cell extracts and in conditioned extracellular media prepared from transfected A375SM cells (Figure 1b) . In cell extracts, the amount of the V5-tagged procathepsin L was significantly increased by the intracellular expression of anti-CTSLScFv (lanes 2-4), as compared with control (lane 1). In extracellular media, secretion of V5-tagged procathepsin L was strongly inhibited by the intracellular expression of anti-CTSL-ScFv linked to cathepsin L peptide signal (lane 2) or to intron-containing mouse V H chain sp (lane 4) and, at a significant lower level, when linked to intronless mouse V H chain sp (lane 3).
Then, we generated lentiviral constructs encoding anti-CTSL-ScFv linked to these different sps. A375SM melanoma cells were transduced in vitro with these anti-CTSL-ScFv lentiviral constructs or with a lentiviral vector without anti-CTSL-ScFv, using the same viral p24 antigen concentration. As shown in Figure 1c Figure 1d ). In addition, cells transduced with the anti-CTSL-ScFv lentiviral construct carrying cathepsin L peptide signal, showed the highest ScFv expression (Figure 1c, lane 2) and the strongest inhibition of procathepsin L secretion (Figure 1d, lane 4) , as compared to other constructs ( Figure 1d, lanes 2 and 3) . Altogether, these data led us to select the lentiviral vector encoding anti-CTSL-ScFv coupled to cathepsin L sp.
In addition, to improve the efficiency of the anti-CTSLScFv lentiviral vector, several modifications were introduced into this construct (Figure 2 ). Schematic representations of these modifications are shown in Figure 2a (Figure 3c, lanes 1-3) .
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Thus, from all the above data, we selected the plenti6-cPPT-spCTSL-anti-CTSL-ScFv-IRES-AcGFP-WPRE construct, named the anti-CTSL-ScFv lentiviral vector, which was the most efficient to transduce intracellular expression of anti-CTSL-ScFv into human melanoma cells. The plenti6-cPPT-spCTSL-IRES-AcGFP-WPRE construct, without anti-CTSL-ScFv cDNA, was used as the control lentiviral vector.
Transduction efficiency of lentiviral vectors
To establish the optimal conditions of transduction, A375SM human melanoma cells were transduced in vitro with the anti-CTSL-ScFv lentiviral vector or the control lentiviral vector at various MOIs (Figure 4 ). Five days after transduction, AcGFP expression was monitored by fluorescence microscopy (Figure 4a) , and the fluorescence intensity was quantified (Figure 4b ). Anti-CTSL-ScFv or control lentiviral vectors transduced A375SM cells with the same efficiency. Fluorescence microscopy analysis of A375SM cells, transduced at an MOI of 5, showed AcGFP expression in more than 98% of cells (Figure 4a ). The percentage of AcGFP-positive cells was stable at least during 2 months in transduced cells maintained in culture.
Adding more lentiviral constructs resulted in an increase in the fluorescence intensity, most likely due to the entry of multiple lentiviral copies into the cells (Figure 4b ). However, cell death became significant when MOI values were higher than 10. Thus, an MOI of 10 was routinely used to transduce human melanoma cells with these lentiviral constructs.
Immunofluorescence analysis was performed on A375SM cells transduced with these lentiviral constructs (Figure 4c ). Anti-CTSL-ScFv expression was clearly detected in AcGFPpositive cells in A375SM cells transduced with the anti-CTSL-ScFv lentiviral vector (bottom panels). In control, as expected, A375SM cells transduced with control lentiviral vector, were not stained with anti-myc tag moAb (middle panel 3). These data demonstrated that AcGFP-positive cells indeed expressed anti-CTSL-ScFv.
In vitro growth of melanoma cells transduced with lentiviral constructs
In vitro growth of A375SM cells transduced by anti-CTSL-ScFv or control lentiviral vectors was analyzed. 
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Data demonstrated that the growth rate of transduced A375SM cells was similar to that of A375SM parental cells (Figure 4d ). Thus, transduction by these lentiviral vector constructs and the intracellular expression of anti-CTSL-ScFv did not modify in vitro cell proliferation.
Inhibition of procathepsin L secretion induced in hypoxic conditions
We analyzed the level of procathepsin L secretion in A375SM melanoma cells grown under hypoxic or normoxic conditions. As shown in Figure 5 Tumor inhibition by anti-cathepsin L ScFv delivery R Frade et al control-lentiviral vector or anti-CTSL-ScFv lentiviral vector was intratumor injected. Identical patterns were obtained in three identical experiments performed at different periods, using the same protocol. We also analyzed by immunofluorescence staining the tissue sections of tumors removed from mice killed at day 35 and in which control or anti-CTSL-ScFv lentiviral vectors were intratumor injected (red lines 4 and 5 of Figure 6 ). Staining demonstrated that anti-CTSL-ScFv intratumors injected at days 7 and 10 were indeed expressed in tumor cells at day 35 but with a heterogeneous distribution in the cells labeled and in the intensity of positive spots ( Figure 7) . However, despite this heterogeneity, intratumor injection of the anti-CTSL-ScFv lentiviral vector triggered 69% inhibition of the growth of tumors induced by human melanoma cells.
Inhibition of tumor angiogenesis by intratumoral injection of anti-CTSL-ScFv lentiviral vector
We analyzed the level of tumor angiogenesis in the experiments described above in the mice killed at day 35. Tumor-associated neovascularization, indicated by MVD, was quantified by immunohistochemistry using anti-CD31 antibody. As shown in Figure 8a , the mean MVD was at a maximum of 30±3.5% for tumors induced by untreated A375SM parental cells (row 1) and was very similar for tumors produced by A375SM cells pre-transduced with control lentiviral vector (row 2) or for tumors injected with control lentiviral vector (row 4). However, the mean MVD was strongly reduced to 2.5 ± 0.2% in small tumors induced late with A375SM 
Discussion
Our aim was to determine whether human tumors already growing s.c. in nude mice could be inhibited by afterwards intratumoral expression of anti-CTSL-ScFv, which inhibits procathepsin L secretion.
Indeed, previously we clearly demonstrated that highly tumorigenic and metastatic phenotype of human melanoma cells is associated with procathepsin L secretion. This demonstration was supported by three different and complementary results, as: (1) before injection in nude mice, preincubation of human melanoma cells with polyclonal anti-CTSL antibody, which inhibits cathepsin L activity, led to inhibited tumor growth; 8 (2) transfection of poorly tumorigenic and non-metastatic human melanoma cells with cathepsin L cDNA, to increase procathepsin L expression and secretion, switched their phenotype to highly tumorigenic and metastatic; 10 (3) in vitro transfection of highly tumorigenic human melanoma cells with anti-CTSL-ScFv, whose expression inhibits procathepsin L secretion, switched their phenotype to non-tumorigenic and poorly metastatic. In this third set of experiments, human melanoma cells were in vitro transfected using this anti-CTSL-ScFv driven by a CMV promoter.
Thus, to transduce in vivo human melanoma cells with this anti-CTSL-ScFv and to obtain stable expression, we first undertook to design an efficient lentiviral vector by generating different constructs. Data led us to select the plenti6-cPPT-spCTSL-anti-CTSL-ScFv-IRES-AcGFP-WPRE construct, named herein as the anti-CTSL-ScFv lentiviral vector, as the most efficient construct, which allowed the highest intracellular expression of anti-CTSLScFv and the strongest inhibition of procathepsin L secretion. In control, we used the plenti6-cPPT-spCTSL-IRES-AcGFP-WPRE, without anti-CTSL-ScFv cDNA, named herein as the control lentiviral vector. In addition, melanoma cells transduced by this anti-CTSL-ScFv lentiviral vector did not show any modification either in their amount or in the ratio of intracellular forms of cathepsin L. We previously demonstrated a similar effect of anti-CTSL-SCFv expression in cells stably transfected. 19 This anti-CTSL-ScFv lentiviral vector was obtained by (1) selecting the most efficient sp. Indeed, we observed that the presence of an intron in the mouse V H chain sp had an opposite effect in transient transfection versus transduction experiments, that is increase versus decrease of anti-CTSL-ScFv expression, respectively. It is well known that the splicing of introns by the spliceosome improves gene expression by influencing all the steps of mRNA synthesis, translation and decay. 22 This supports that the presence of an intron in the sp increased ScFv expression in transient transfection experiments. However, in the transduction experiments, as the genome of retroviruses is an mRNA, the nuclear splicing machinery could remove introns of transgenes during synthesis and processing of viral RNA from engineered provirus. 23 For instance, spliced lentiviral vector was previously observed in genomic DNA of transduced cells. 24 The backbone of the lentiviral construct used herein contains one 5 0 splice donor site and two 3 0 splice acceptor sites that encompass the packaging signal (C) and the Rev response element (RRE). Thus, we cannot exclude that splicing occurs between known or cryptic splice sites located into the lentiviral vector backbone and sp splice site. This splicing could generate a lentiviral vector with truncated ScFv cDNA and consequently trigger inhibition of ScFv expression with the intron-containing lentivirus vector in transduction experiments. Furthermore, our data showed that cathepsin L sp was more efficient than sps from mouse V H chain. A difference in the property of sps to direct protein to the endoplasmic reticulum was described in eukaryotic cells. 25 Incorporation of the cathepsin L 5 0 -UTR 20 to its sp did not improve ScFv expression; (2) introducing into our lentiviral vector construct, cis-acting regulatory sequences, which were described to enhance transduction and transgene expression, 26 as the WPRE and the HIV-1 cPPT. We analyzed their effects on ScFv expression using our lentiviral vector backbone and in melanoma cells, whereas their insertions into other lentiviral constructs failed to improve and even impaired the expression level of the transgene into transduced tumor cells. 27, 28 The WPRE induced a weak increase of anti-CTSL-ScFv expression in both monocistronic and bicistronic lentiviral vectors, but cPPT allowed a strong increase of anti-CTSL-ScFv expression. To quantify the viral titer and the transduction efficiency, the reporter gene AcGFP was also introduced in the lentiviral vector under the control of the IRES of the encephalomyocarditis virus, known to mediate internal initiation of translation in a broad range of host cells. 29 Second, we analyzed the effect of this anti-CTSL-ScFv lentiviral vector on in vitro proliferation of transduced human melanoma cells. Data led us to select an MOI of 10 to obtain at least 98% of transduced cells, without modifying cell growth or inducing in vitro cell death. This confirmed that overexpression of anti-CTSL-ScFv is not cytotoxic in human melanoma cells after transduction as well as in transfection experiments. 19 Third, we herein demonstrated clearly that injection of anti-CTSL-ScFv lentiviral vector into tumors already induced in nude mice inhibits the growth of these tumors, as compared with control lentiviral vector. Indeed, data demonstrated that 24 days after intratumor injections of anti-CTSL-ScFv lentiviral vectors, 69% of tumor growth was inhibited. The inhibition of tumor growth was also attended by a decrease of tumor vascularization and an increase of the percentage of apoptotic cells. We previously demonstrated that similar correlation existed between tumor growth, percentage of apoptotic cells and tumor vascularization in tumors induced by human melanoma cells stably transfected with anti-CTSLScFv. 19 In addition, we herein demonstrated that procathepsin L secretion was strongly increased in human melanoma cells grown under hypoxia. The specificity of the increase of procathepsin L secretion was supported by the absence of modification of MMP-2 secretion in human melanoma cells grown under identical experimental conditions. It is well known that hypoxia occurs rapidly during in vivo tumor cell growth and has a strong impact on tumor cell biology, contributing to tumor progression by a diversity of mechanisms. 30, 31 Thus, procathepsin L secretion emerged as a new molecular mechanism induced by hypoxia in human melanoma cells. Furthermore, this increase of procathepsin L secretion was fully inhibited in melanoma cells transduced in vitro by anti-CTSL-ScFv lentiviral vector, supporting the high efficiency of this specific ScFv molecular tool.
Data supported the involvement of procathepsin L secretion in tumor growth and also in related angiogenesis: (1) on tumor growth: the exact mechanism through which in vivo secreted procathepsin L could contribute remains unknown. One possibility could be that secreted procathepsin L, under proenzyme and/or mature forms, cleaved extracellular substrates in tumor microenvironment, as we have already demonstrated for human C3, the third component of complement. [7] [8] [9] [10] Another possibility could be that procathepsin L might also act as a paracrine factor, through specific receptors expressed on tumor or host cells. Although no data yet support a putative paracrine function of cathepsin L, this was clearly demonstrated for cathepsin D, a lysosomal proteinase also involved in tumor growth. Indeed, procathepsin D, mutated in the way to be devoid of its catalytic activity, continued to stimulate growth of tumor cells by acting as a paracrine factor; 32, 33 (2) on angiogenesis: it was described by others that cathepsin L, as a pericellular protease, stimulates the recruitment and action of blood or bone-marrow-derived accessory cells that enhance angiogenesis. 34 Cathepsin L contributes to modify tumor microenvironment, by generating fragments of extracellular matrix and hemostasis factors that have angiogenic properties. 34 In addition, it was shown that cathepsin L is required for neovascularization into ischemic tissues. 35 Further studies are needed to establish the exact contribution of secreted procathepsin L on tumor growth and tumor-related vascularization induced by human melanoma cells. Intratumoral injection of anti-CTSL-ScFv lentiviral vector, although 69% efficient, did not totally inhibit tumor growth. Our data suggested that this is most likely related to the in vivo accessibility of tumor cells by anti-CTSL-ScFv lentiviral vector and to the level of anti-CTSL-ScFv expression into transduced tumor cells. First, although up to 98% of human melanoma cells transduced in vitro expressed the anti-CTSL-ScFv, they exhibited a heterogeneous expression of this anti-CTSL-ScFv (Figure 4) . Second, the immunostaining of tissue sections of tumors injected with anti-CTSL lentiviral vector and removed at day 35 also demonstrated a heterogeneous expression of anti-CTSL-ScFv in tumor cells, some being unstained and others expressing a large staining diversity (Figure 8 ). It was also demonstrated that lentiviral vector efficiency is reduced in vivo, using gene reporter. 36 In addition, we observed that depending on the size and the shape of induced tumors, the 100 ml injection volume did not allow the anti-CTSL-ScFv lentiviral vector sample to spread into the tumor, probably preventing all tumor cells from becoming in situ transduced. Furthermore, a difference in the level of anti-CTSL-ScFv expression between in vivo transduced cells could also introduce a discrepancy in the growth of these tumor cells. Indeed, we previously demonstrated, by selecting two stably transfected human melanoma clones that expressed two different amounts of anti-CTSL-ScFv, that these two clones triggered two different inhibition levels of procathepsin L secretion and tumor growth. 19 Third, the immunostaining of tissue sections prepared from the small tumors produced by in vitro pre-transduced cells, detectable only at day 25 and collected at day 35, did not allow to detect any anti-CTSL-ScFv expression (data not shown). These data suggested that some tumor cells escaped from transduction by the anti-CTSL-ScFv lentiviral vector and consequently did not express this ScFv. Thus, cathepsin L secretion was not inhibited and its accumulation in the vicinity of tumor cells facilitates their growth, even after a delay. These data supported that in situ anti-CTSL-ScFv lentiviral vector delivery in tumor cells needs to be improved to increase accessibility of tumor cells and consequently to induce the highest yield of anti-CTSL-ScFv intracellular expression to totally inhibit procathepsin L secretion.
In conclusion, overall and for the first time, we herein clearly demonstrated that targeting procathepsin L secretion by intratumoral injection of anti-CTSL-ScFv lentiviral vector represents a new gene therapy that should be helpful to inhibit the growth of tumors induced by human melanoma cells.
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